Sugi Predict

Sugi Predict / Targets / S1PR2

S1PR2

Sphingosine 1-phosphate receptor 2 · O95136 · S1PR2 on Sugi Atlas →

71,253 patent compounds predicted against S1PR2, 41,067 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL36045 SCHEMBL36045 0.59 17/20
SCHEMBL35944 SCHEMBL35944 0.58 15/20
SCHEMBL36110 SCHEMBL36110 0.58 15/20
SCHEMBL35933 SCHEMBL35933 0.58 12/20
SCHEMBL36123 SCHEMBL36123 0.57 12/20
SCHEMBL36206 SCHEMBL36206 0.57 12/20
SCHEMBL35848 SCHEMBL35848 0.56 12/20
SCHEMBL35951 SCHEMBL35951 0.56 12/20
SCHEMBL36013 SCHEMBL36013 0.56 12/20
SCHEMBL78519 SCHEMBL78519 0.53 12/20
SCHEMBL36218 SCHEMBL36218 0.44 12/20
SCHEMBL19906 SCHEMBL19906 0.68 11/20
SCHEMBL33472 SCHEMBL33472 0.68 11/20
SCHEMBL35167 SCHEMBL35167 0.68 11/20
SCHEMBL107866 SCHEMBL107866 0.68 11/20
SCHEMBL110008 SCHEMBL110008 0.68 11/20
SCHEMBL121170 SCHEMBL121170 0.68 11/20
SCHEMBL194178 SCHEMBL194178 0.68 11/20
SCHEMBL35831 SCHEMBL35831 0.58 11/20
SCHEMBL35626 SCHEMBL35626 0.57 11/20

Clinical trials — most relevant to S1PR2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Eicosapentaenoic Acid Cerebral Vasospasm Therapy Study PHASE4COMPLETED
Sphingosine-1-phosphate and Pneumonia PHASE2/PHASE3UNKNOWN
Evaluating of the Effect of Fingolimod With Fish Oil on Relapsing-Remitting Multiple Sclerosis Patients PHASE2/PHASE3COMPLETED
Phase 2 Study of Fingolimod in Lung Cancers PHASE2RECRUITING
Repurposing Siponimod for Alzheimer's Disease PHASE2RECRUITING
Fingolimod in Schizophrenia Patients PHASE2COMPLETED
Fingolimod for the Abrogation of Interstitial Fibrosis and Tubular Atrophy Following Kidney Transplantation PHASE2ENROLLING_BY_INVITATION
Efficacy and Safety of FTY720 for Acute Stroke PHASE2COMPLETED
A Study to Assess the Relative Bioavailability of Different Formulations of GSK2018682, a Sphingosine-1-phosphate Receptor Subtype 1 Agonist, in Healthy Volunteers. PHASE1COMPLETED
Dose Escalation Study of the Pharmacodynamics, Pharmacokinetics, Safety, and Immunogenicity of BCD-132 in Patients With Relapsing-Remitting Multiple Sclerosis PHASE1COMPLETED
Safety Study of ASONEP (Sonepcizumab/LT1009) to Treat Advanced Solid Tumors PHASE1COMPLETED
Evaluation of Plasma Sphingosine-1-Phosphate as A Diagnostic and Prognostic Biomarkers of Community-Acquired Pneumonia nanUNKNOWN
Vulvodynia: Identification of Potential Relevant Biomarkers nanCOMPLETED
Longitudinal Assessment of Marrow and Blood in Patients With Glioblastoma nanSUSPENDED
Effects of Ozanimod on Immune-mediated Mechanisms of Neurodegeneration in Multiple Sclerosis - a Preclinical Study nanUNKNOWN
Effects of Fingolimod on Heart Rhythm and Heart Rate Variability in Patients With Multiple Sclerosis nanUNKNOWN
Identification of Biomarkers and Molecular Targets Involved on Intervertebral Disc Degeneration and Discogenic Pain nanUNKNOWN
Development of Therapeutic Approaches Modulating Molecular Targets Implicated on Cancer Stem Cell-related Aggressiveness nanUNKNOWN
Studying Lipids as Potential Biomarkers in Patients With Fabry Disease nanCOMPLETED
Evaluating the Association Between Sphingolipid Metabolites and Post-hepatectomy Liver Failure nanCOMPLETED
Investigation of Inflammation Using [C-11]-CS1P1 nanACTIVE_NOT_RECRUITING
Evaluation of Serum Ceramides C16, C24, and Sphingosine-1-Phosphate (S1P) in Patients With Acne Vulgaris nanNOT_YET_RECRUITING
Analysis of a Biomarker Signature in Patients With Multiple Sclerosis (MS) Treated With Gilenya (FTY720) nanUNKNOWN
Assessment of Immune Response in Multiple Sclerosis Patients With COVID-19/Vaccination Treated With Ofatumumab and Other Disease Modifying Therapies nanCOMPLETED
Effect of Plasma Ceramides on Peripheral Vascular Function nanCOMPLETED
Plasma Dihydroceramides Are Associated With Hepatic Steatosis in Type 1 and Type 2 Diabetes nanCOMPLETED
Plasma Sphingolipid Metabolites and Radiotherapy Efficacy in Hepatocellular Carcinoma nanRECRUITING
The ASTERS Study: Assessing the Role of Sphingolipids in AcuTE Respiratory Distress Syndrome (ARDS) nanCOMPLETED
Ceramide Level as Apredictor of Outcomes in Patients of Anterior Myocardial Infarction Undergoing Primary Coronary Intervention nanUNKNOWN
Investigating the Metabolic and Lipidomic Profiles That Are Associated With Varying Grades of Diabetic Maculopathy and Retinopathy in South Wales nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a S1PR2 binder may also engage these)

ProteinNameSimilarity
P47752 — 1.000 P47752 →
P52592 — 0.997 P52592 →
CNR2 Cannabinoid receptor 2 0.986 landscape →
Q9QZN9 — 0.980 Q9QZN9 →
P47936 — 0.978 P47936 →
Q9PUQ8 — 0.978 Q9PUQ8 →
Q9Z0L1 — 0.977 Q9Z0L1 →
Q62053 — 0.975 Q62053 →
PTGER2 Prostaglandin E2 receptor EP2 subtype 0.970 landscape →
P11617 — 0.970 P11617 →
Q9DDK4 — 0.970 Q9DDK4 →
B4XF06 — 0.969 B4XF06 →
Q9R261 — 0.969 Q9R261 →
Q62928 — 0.968 Q62928 →
Q60613 — 0.968 Q60613 →
LPAR2 Lysophosphatidic acid receptor 2 0.966 landscape →
S1PR4 Sphingosine 1-phosphate receptor 4 0.966 landscape →
Q9XT82 — 0.966 Q9XT82 →
O08530 — 0.966 O08530 →
Q9Z0U9 — 0.966 Q9Z0U9 →
P46069 — 0.966 P46069 →
Q9I8K8 — 0.965 Q9I8K8 →
P30557 — 0.965 P30557 →
P34980 — 0.964 P34980 →
Q95KH4 — 0.964 Q95KH4 →
S1PR1 Sphingosine 1-phosphate receptor 1 0.964 landscape →
PTGER3 Prostaglandin E2 receptor EP3 subtype 0.964 landscape →
P70263 — 0.964 P70263 →
O35932 — 0.964 O35932 →
Q6TLI7 — 0.964 Q6TLI7 →